Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -139.74 Million SEK | 26.28% |
| 2022 | -189.57 Million SEK | 23.35% |
| 2021 | -247.32 Million SEK | 64.33% |
| 2020 | -693.35 Million SEK | -1639.04% |
| 2019 | -39.87 Million SEK | 47.9% |
| 2018 | -76.52 Million SEK | 48.91% |
| 2017 | -149.78 Million SEK | -478.22% |
| 2016 | -25.9 Million SEK | -168.69% |
| 2015 | -9.64 Million SEK | 42.13% |
| 2014 | -16.65 Million SEK | -1013.36% |
| 2013 | -1.49 Million SEK | 43.58% |
| 2012 | -2.65 Million SEK | -36.97% |
| 2011 | -1.93 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -107.6 Million SEK | 23.0% |
| 2024 Q2 | -84.68 Million SEK | 21.3% |
| 2023 FY | -139.74 Million SEK | 26.28% |
| 2023 Q2 | -158.91 Million SEK | -2.24% |
| 2023 Q3 | -120 Million SEK | 24.49% |
| 2023 Q4 | -139.74 Million SEK | -16.45% |
| 2023 Q1 | -155.44 Million SEK | 18.01% |
| 2022 Q4 | -189.57 Million SEK | 27.01% |
| 2022 Q1 | -205.68 Million SEK | 16.84% |
| 2022 Q2 | -114.11 Million SEK | 44.52% |
| 2022 FY | -189.57 Million SEK | 23.35% |
| 2022 Q3 | -259.73 Million SEK | -127.61% |
| 2021 Q2 | -94.67 Million SEK | 46.33% |
| 2021 Q3 | -335.88 Million SEK | -254.77% |
| 2021 Q4 | -247.32 Million SEK | 26.37% |
| 2021 Q1 | -176.41 Million SEK | 74.56% |
| 2021 FY | -247.32 Million SEK | 64.33% |
| 2020 FY | -693.35 Million SEK | -1639.04% |
| 2020 Q3 | -282 Million SEK | -13.58% |
| 2020 Q2 | -248.29 Million SEK | -4.69% |
| 2020 Q4 | -693.35 Million SEK | -145.87% |
| 2020 Q1 | -237.18 Million SEK | -494.89% |
| 2019 Q2 | -59.17 Million SEK | 63.21% |
| 2019 Q1 | -160.85 Million SEK | -110.19% |
| 2019 FY | -39.87 Million SEK | 47.9% |
| 2019 Q4 | -39.87 Million SEK | -15.47% |
| 2019 Q3 | -34.52 Million SEK | 41.65% |
| 2018 Q4 | -76.52 Million SEK | 5.16% |
| 2018 Q3 | -80.69 Million SEK | 21.5% |
| 2018 FY | -76.52 Million SEK | 48.91% |
| 2018 Q1 | -80.58 Million SEK | 46.2% |
| 2018 Q2 | -102.78 Million SEK | -27.56% |
| 2017 Q4 | -149.78 Million SEK | -362.5% |
| 2017 FY | -149.78 Million SEK | -478.22% |
| 2017 Q1 | -63.73 Million SEK | -146.05% |
| 2017 Q2 | -46.47 Million SEK | 27.08% |
| 2017 Q3 | -32.38 Million SEK | 30.32% |
| 2016 Q3 | -20.07 Million SEK | 34.84% |
| 2016 FY | -25.9 Million SEK | -168.69% |
| 2016 Q4 | -25.9 Million SEK | -29.06% |
| 2016 Q2 | -30.8 Million SEK | -1071.66% |
| 2016 Q1 | -2.62 Million SEK | 72.73% |
| 2015 Q2 | -18.77 Million SEK | 51.83% |
| 2015 FY | -9.64 Million SEK | 42.13% |
| 2015 Q1 | -38.98 Million SEK | -134.01% |
| 2015 Q4 | -9.64 Million SEK | 28.57% |
| 2015 Q3 | -13.49 Million SEK | 28.12% |
| 2014 Q4 | -16.65 Million SEK | -259.03% |
| 2014 Q1 | 1.49 Million SEK | 200.0% |
| 2014 FY | -16.65 Million SEK | -1013.36% |
| 2014 Q3 | -4.64 Million SEK | 0.0% |
| 2013 Q4 | -1.49 Million SEK | 0.0% |
| 2013 FY | -1.49 Million SEK | 43.58% |
| 2012 FY | -2.65 Million SEK | -36.97% |
| 2011 FY | -1.93 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -179.377% |
| Ziccum AB (publ) | -2.13 Million SEK | -6439.401% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -633.195% |
| BioArctic AB (publ) | -606.58 Million SEK | 76.962% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -179.863% |
| Mendus AB (publ) | -96.29 Million SEK | -45.125% |
| Genovis AB (publ.) | -43.94 Million SEK | -218.033% |
| Intervacc AB (publ) | -88.16 Million SEK | -58.515% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 781.36% |
| Active Biotech AB (publ) | -33.2 Million SEK | -320.925% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 362.569% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -254.85% |
| Aptahem AB (publ) | 2.9 Million SEK | 4904.545% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 58.112% |
| Kancera AB (publ) | -45.69 Million SEK | -205.846% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 57.532% |
| Fluicell AB (publ) | -2.76 Million SEK | -4957.799% |
| Saniona AB (publ) | 40.44 Million SEK | 445.506% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -337.708% |
| Biovica International AB (publ) | -58.73 Million SEK | -137.92% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -209.059% |
| AcouSort AB (publ) | -23.98 Million SEK | -482.619% |
| Xintela AB (publ) | -7.8 Million SEK | -1689.563% |
| Abliva AB (publ) | -57.24 Million SEK | -144.142% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 28.224% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -70.004% |
| OncoZenge AB (publ) | -12.62 Million SEK | -1006.732% |
| Amniotics AB (publ) | -5.63 Million SEK | -2381.303% |
| 2cureX AB (publ) | -13.4 Million SEK | -942.655% |
| CombiGene AB (publ) | -101.44 Million SEK | -37.763% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -6366.775% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 2687.907% |
| Camurus AB (publ) | -1.16 Billion SEK | 88.008% |
| Corline Biomedical AB | -17.01 Million SEK | -721.461% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -66.876% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -1.157% |
| I-Tech AB | -83.26 Million SEK | -67.84% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 203.741% |
| Cyxone AB (publ) | -16.67 Million SEK | -738.314% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -150.057% |
| Biosergen AB | -1.88 Million SEK | -7321.508% |
| NextCell Pharma AB | -46.79 Million SEK | -198.665% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -7.917% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -375.605% |
| Nanologica AB (publ) | -9.38 Million SEK | -1388.571% |
| SynAct Pharma AB | -61.75 Million SEK | -126.282% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -552.566% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -956.354% |
| LIDDS AB (publ) | -13.51 Million SEK | -934.244% |
| Lipum AB (publ) | -8.46 Million SEK | -1550.88% |
| BioInvent International AB (publ) | -236.3 Million SEK | 40.861% |
| Alzinova AB (publ) | -21.22 Million SEK | -558.377% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -108.827% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -2597.339% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -66.88% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -15040.52% |
| Simris Alg AB (publ) | 85.07 Million SEK | 264.263% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -70.245% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 184.146% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -572.087% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -4602.12% |